Skip to main content

Advertisement

Table 1 Patient characteristics

From: Restoration of regulatory and effector T cell balance and B cell homeostasis in systemic lupus erythematosus patients through vitamin D supplementation

Characteristics N = 20
Epidemiology  
Age, y, mean ± SD 31 ± 8
Female gender, n (%) 20 (100)
Previous SLE manifestations  
Skin, n (%) 11 (55)
Joints, n (%) 9 (45)
Serositis, n (%) 4 (20)
Kidney, n (%) 11 (55)
Central nervous system, n (%) 1 (5)
SELENA-SLEDAI at Day 0, mean (range) 2 (0 to 8)
25-Hydroxyvitamin D levels  
Mean ± SD, ng/mL 22 ± 11
25(OH)D ≤ 10 ng/mL, n (%) 1 (5)
11 < 25(OH)D ≤ 20 ng/mL, n (%) 11 (55)
21 < 25(OH)D ≤ 30 ng/mL, n (%) 8 (40)
Associated treatments*  
Prednisone, n (%) 14 (70)
Prednisone, median, mg/day (range) 5 (0 to 15)
Hydroxychloroquine, n (%) 17 (85)
Azathioprine, n (%) 2 (10)
Mycophenolate mofetil, n (%) 1 (5)
  1. *At the time of the study. SLE: systemic lupus erythematosus; SELENA-SLEDAI: Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; 25(OH)D: 25-hydroxyvitamin D.